REFERENCES
- Bollag W, Peck R. Modulation of growth and differentiation by retinoids and cytokines. In: Saurat JH, ed. Retinoids: 10 years on. Basel: Karger, 1991: 127–38.
- Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentia-tion therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385–93.
- Lippman SM, Kessler JF, Meyskens FL Jr. Retinoids as preventive and therapeutic anticancer agents (part II). Cancer Treat Rep 1987; 71: 493–515.
- Meyskens FL Jr, Gilmartin E, Alberts DS, et al. Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep 1982; 6: 1315–9.
- Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839–64.
- Boyd AS. An overview of the retinoids. Am J Med 1989; 86: 568–74.
- Goldstein D, Laszlo J. The role of interferon in cancer therapy: a current perspective. CA 1988; 38: 258–77.
- Peck R, Bollag W. Potentiation of retinoid-induced differenti-ation of HL-60 and U937 cell lines. Eur J Cancer 1991; 27: 53–7.
- Marth C, Widschwendter M, Daxenbichler G. Mechanism of synergistic action of all-trans- or 9-cis-retinoic acid and inter- ferons in breast cancer cells. J Steroid Biochem Mol Biol 1993; 47: 123–6.
- Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol 1992; 3: 513–26.
- Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble A-vitamin. J Exp Med 1925; 42: 753–78.
- Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-retinoic acid plus interferon-a: effective therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84: 235–41.
- Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al. 13-cis-retinoic acid plus interferon-a: highly active systemic ther-apy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241–5.
- Saurat J-H. Side effects of systemic retinoids and their clinical management. J Am Acad Dermatol 1992; 27 (Suppl): S23–28.
- Baron S, Tyring SK, Fleischmann WR, Jr, et al. The interfer-ons: mechanisms of action and clinical applications. JAMA 1991; 266: 1375–83.
- Ernstoff MS, Gooding W, Nair S, et al. Immunological effects of treatment with sequential administration of recom-binant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res 1992; 52: 851–6.
- Zachariae H, Threstrup-Pedersen K. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990; 95: 206S–8S.
- Dréno B, Claudy A, Meynadier J, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses if interferon-a2a and etretinate. Br J Dermatol 1991; 125: 456–9.
- Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14.
- Roth AD, Abele R, Alberto P. 13-cis-retinoic acid plus inter-feron-a: a phase II clinical study in squamous cell carcinoma of the lung and the head and neck. Oncology 1994; 51: 846–8.
- Pilkington T, Brogden RN. Acitretin: A review of its pharma-cology and therapeutic use. Drugs 1992; 43: 597–627.
- Williams BR. Transcriptional regulation of interferon-stimu-lated genes. Eur J Biochem 1991; 200: 1–11.
- Lengyel P. Tumor-suppressor genes: news about the inter-feron connection. Proc Natl Acad Sci USA 1993; 90: 5893–5.